Key result
Modern bridge-to-decision MCS increases high-flow PVAD use but yields no 60-day mortality benefit.
Why the study?
With the availability of destination therapy using durable LVADs, how the destination therapy Era has reshaped practice patterns within bridge-to-decision strategies for cardiogenic shock and whether such shifts have translated into improved early outcomes remained uncertain.
Does a bridge-to-decision strategy during the destination therapy era reduce 60-day mortality compared to the pre-destination therapy era in patients with cardiogenic shock receiving temporary mechanical circulatory support?
Cohort (n=191)
No
Does a bridge-to-decision strategy during the destination therapy era reduce 60-day mortality compared to the pre-destination therapy era in patients with cardiogenic shock receiving temporary mechanical circulatory support?
Answers are grounded in this paper and cite their sources.
Despite a significant shift toward greater adoption of high-flow percutaneous ventricular assist devices in the destination therapy era for cardiogenic shock bridge-to-decision strategies, 60-day mortality remained unchanged, with advanced age and ischemic cardiomyopathy persistently identifying high-risk subgroups.
Background Cardiogenic shock (CS) frequently requires temporary mechanical circulatory support (MCS) as part of a bridge-to-decision (BTD) strategy. With the availability of destination therapy (DT) using durable left ventricular assist devices (LVADs), treatment pathways have evolved. However, how the DT Era has reshaped practice patterns within BTD strategies and whether such shifts have translated into improved early outcomes remain uncertain. Purpose To describe changes in device utilization and patient outcomes within a BTD strategy before and after the introduction of the DT Era, and to identify consistently high-risk subgroups. Methods In this single-center retrospective cohort study, we analyzed patients with CS who received their first BTD device between January 2017 and December 2025. Temporary MCS devices included extracorporeal LVAD and high-flow percutaneous ventricular assist devices (PVADs). Patients were categorized into a pre-DT Era group (January 2017–April 2021) and a DT Era group (May 2021–December 2025). The primary outcome was 60-day mortality. Prespecified subgroup analyses focused on age ≥65 years and ischemic cardiomyopathy (ICM). Results Among 191 patients (pre-DT Era: n=104; DT Era: n=87), the use of high-flow PVAD increased markedly from 27.9% to 54.0% in the DT Era (p<0.01), indicating a substantial shift in device allocation. Overall 60-day mortality was 17.8%, with no significant difference between the Eras (17.3% vs. 18.4%, p=0.82). Age ≥65 years and ICM consistently conferred higher risk across both periods (≥65 years: pre-DT Era 50.0% vs. 13.0%, p=0.01; DT Era 45.5% vs. 14.5%, p<0.01; ICM: pre-DT Era 32.4% vs. 9.0%, p<0.01; DT Era 35.7% vs. 10.2%, p<0.01). Conclusions In the DT Era, clinical practice within the BTD strategy shifted toward greater adoption of high-flow PVADs, yet early outcomes remained comparable to those in the pre-DT Era. This discrepancy may reflect the expanded application of BTD strategies to higher-risk patients or persistent constraints in device–patient matching and timing. Across Eras, advanced age and ICM consistently identified high-risk subgroups, underscoring the need for refined risk stratification and optimization of BTD algorithms in the DT Era.
No takes yet. Share an insight, caveat, or question.
Tomita et al. (2026) conducted a cohort in Cardiogenic shock (n=191). Destination Therapy (DT) Era bridge-to-decision strategy (May 2021–December 2025) vs. Pre-Destination Therapy (pre-DT) Era bridge-to-decision strategy (January 2017–April 2021) was evaluated on 60-day mortality (p=0.82). Bridge-to-decision MCS in the DT Era increased high-flow PVAD use but showed comparable 60-day mortality to the pre-DT Era.
Synapse has enriched 10 related papers. Consider them for comparative context: